Pfizer Beat and Raised Again, but at $30 the Market Has Already Paid for the Turnaround

Results vs. Consensus

Pfizer reported before the open on Tuesday, November 3, 2026, the day of the US midterm elections, and hosted its call at 10:00 AM. The print beat on both lines for the fourth consecutive quarter in our coverage. What changed is not the business, which is executing at the best pace we have seen, but the price at which an investor now buys it.

Q3 2026 Scorecard

Product rows compare with one tracked estimate rather than a multi-source consensus.

Year-over-Year Comparison

Flat adjusted EPS hides two offsetting moves. Acquired IPR&D fell by about $720M (Innovent this year against 3SBio last year), while the tax rate rose 6.1 points and adjusted R&D rose $456M. Excluding acquired IPR&D in both years, adjusted pre-tax income was about $6,475M against $6,774M, down roughly 4%.

Sequential Comparison (QoQ)

Reading the Three Lines

Revenue. Total revenue was flat year over year at $16,583M because the COVID franchise fell by $1,119M, to $1,257M from $2,376M. Everything else grew 7% operationally, matching the first quarter's 7% and up from 5% in the second. The geography split favours the US for once in a constructive way: US Oncology grew 15% and US Specialty Care 4%, while US Primary Care fell 12% entirely because of COVID and Prevnar. The quality caveat is the size of the Eliquis contribution, which we take apart in the Key Topics below. With Eliquis and COVID both removed, revenue grew 4.4%, which is a credible engine but a less spectacular one than the headline 7%.

Margins. Adjusted gross margin of about 77% improved roughly 70 basis points year over year, which management attributed to favourable product mix and cost management. That is a better result than it looks, because last year's third quarter carried a favourable royalty accrual revision that the release says did not recur. Adjusted operating margin of about 36% was achieved while adjusted R&D rose 18% operationally on oncology and obesity Phase 3 starts and the quarter absorbed $669M of acquired IPR&D. The full-year R&D guide moved up $300M to $10.8–11.8B, so the higher spending rate is planned rather than a one-off.

EPS. Adjusted EPS of $0.87 was flat year over year and 19% ahead of consensus. Nine-month adjusted EPS is $2.39, down 7% from $2.56, an improvement on the 10% first-half decline. Reported EPS of $0.56 fell 9% even though reported pre-tax income rose 2%, because last year's quarter carried a tax benefit from deferred-tax remeasurement. Restructuring charges for cost-reduction initiatives also rose to $742M (total restructuring charges were $753M), mostly employee termination costs from the cost realignment programme. Unlike the second quarter there was no intangible impairment, which is the first clean quarter on that line since we added it as a bear point.

Segment Performance

Pfizer reports one Biopharma segment plus Pfizer CentreOne, and discloses revenue by four commercial categories under the structure adopted in January, with prior-year figures restated. The product detail below is comparable across our coverage.

Product Detail

Primary Care

Primary Care fell 9% operationally to $6,971M, but without Comirnaty and Paxlovid it grew about 8.5% to $5,714M. Eliquis did most of that lifting at $2,523M, up 25% operationally, with US revenue up 40% to $1,808M and international revenue slightly lower as generics enter some markets. Nurtec grew 33% to $547M on US demand and new international launches, which puts it near the $2B annualized level the CEO cited on the call. The weak spots are the vaccines: Prevnar fell 10% operationally, and Abrysvo's 9% growth came entirely from international launches while US sales fell 33% on unfavourable buying patterns and lower vaccination rates.

"Eliquis globally, up $513 million, or 25%, operationally, driven primarily by higher net price in the U.S. primarily due to pricing dynamics, including lower rebates and channel mix favorability, as well as higher demand globally" — Pfizer third-quarter 2026 earnings release

Assessment: The category is healthier than its headline, but its growth is concentrated in the one product with the nearest exclusivity clock. The vaccine line is now the real problem inside Primary Care: two of its three vaccines lost ground in the US in the same quarter, and the third is COVID.

Oncology

Oncology grew 10% operationally to $4,327M, the strongest quarter in our coverage and up from 2% in the second quarter. Padcev grew 55% to $720M on first-line share in metastatic urothelial cancer and early uptake in the cisplatin-ineligible muscle-invasive indication. Lorbrena grew 43%, Orgovyx 37%, Tukysa 30% and Braftovi/Mektovi 21%. Ibrance grew 3% operationally, with US revenue up 14% on higher demand, favourable buying patterns and higher net price. Xtandi fell 6% and Bosulif 52%.

"Our legacy Seagen portfolio grew 39% year over year in The U. S. In the quarter, driven by the strong performance of Padcev" — Albert Bourla, Chairman & CEO

Assessment: The Seagen assets are now unambiguously working, and the October approvals for Tukysa in frontline maintenance and for Talzenna with Xtandi in an earlier prostate setting add label breadth. The caution is Ibrance: a 14% US gain that leans partly on buying patterns, in the year before the drug loses US exclusivity and takes a negotiated Medicare price, is a gain we would not extrapolate.

Specialty Care

Specialty Care grew 7% operationally to $3,349M. The Vyndaqel family grew 12% operationally to $1,773M, an acceleration from 8% in the second quarter, with US revenue up 14% on continued market expansion and international up 9% operationally on diagnosis uptake and improved access. Octagam grew 18% and Cibinqo 26%. Xeljanz fell 32%, with US revenue down 49%.

"Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up $193 million, or 12%, operationally, driven primarily by continued market expansion in the U.S., as well as strong demand with continuing uptake in patient diagnosis across international markets and improved access in certain international markets" — Pfizer third-quarter 2026 earnings release

Assessment: This is the category that best supports the long-term case. Vyndaqel is now growing double digits again with US exclusivity running to mid-2031, so the franchise that was the largest cliff exposure at our initiation has become a growth contributor that outlasts the Eliquis exclusivity loss by three years.

Hospital and Biosimilars

Hospital and Biosimilars grew 2% operationally to $1,635M. The US business grew 17%, led by oncology biosimilars (up 20% globally) and Inflectra, while international revenue fell 11% operationally, with Sulperazon down 41% and Zithromax down 37%.

"Effective January 1, 2026, the commercial structure within the Biopharma reportable segment is composed of the Pfizer U.S. Commercial Division, the Pfizer International Commercial Division and the Global Hospital and Biosimilars Division." — Pfizer third-quarter 2026 earnings release

Assessment: This is a low-growth, cash-generative category whose role in the thesis is to not get in the way. It is doing that. The US biosimilar growth is a modest offset to the international erosion of off-patent anti-infectives.

Key KPIs

Q1 2026 product figures are derived from the nine-month totals in this quarter's release less the reported second and third quarters.

Key Topics & Management Commentary

Overall Management Tone: Confident and orderly, with the quarter's tone set by a new permanent CFO presenting a second consecutive raise. Management was more expansive on the pipeline than on the near-term P&L: it spent most of its prepared time on readouts and leaned hard on the claim that the Street under-models the post-2028 business, while keeping 2027 framing qualitative until December. The one place it sounded less convincing was cost: asked why total operating expense has not moved in four years, the answer conceded that savings are being reinvested and that margins will erode through the exclusivity transition.

1. The Second Raise, and What the Fourth-Quarter Arithmetic Says

Full-year revenue guidance rose $1.5B at the midpoint to $62.0–64.0B, and adjusted EPS guidance was raised and narrowed to $2.95–3.05 from $2.80–3.00. Since the original February range the revenue midpoint has risen $2.0B and the EPS midpoint $0.10, while absorbing the $0.10 Innovent charge, so the underlying EPS raise this year is about $0.20. The COVID assumption of approximately $4B was reaffirmed. On revenue the raise was about twice the third-quarter beat against consensus; on EPS it was smaller, $0.10 against $0.14.

"This represents an increase of $0.10 at the midpoint while absorbing the $0.10 per share impact of the Innovent transaction." — Cecile Guegan, Chief Financial Officer

The fourth-quarter math is less generous than the headline. Nine-month revenue of $46,067M and adjusted EPS of $2.39 leave an implied fourth quarter of $15.9B to $17.9B in revenue and $0.56 to $0.66 in adjusted EPS. At the midpoints that is $16.9B and $0.61, against $17,557M and $0.66 a year ago and one tracked pre-print fourth-quarter estimate of $0.71. Take out the roughly $2.0B of COVID revenue the reaffirmed assumption leaves for the fourth quarter and the revenue midpoint implies non-COVID sales about 1% below last year's $15,068M, after 7% growth in the third quarter.

Assessment: Either the guide is conservative or some third-quarter strength was pulled forward, and the evidence leans toward the first. The company has beaten EPS consensus in every quarter of our coverage, and the implied fourth quarter would require a sharp deceleration the call did not describe. Still, a $0.14 beat that becomes a $0.10 raise, with a fourth-quarter range at or below last year, is not the guide of a company trying to get ahead of the Street. The full-year consensus moved to about $3.01, near the upper half of the range, which is where we would expect it to land.

2. Eliquis Carried Half the Non-COVID Growth

Eliquis added $508M year over year, against $1,048M of total non-COVID growth. US Eliquis revenue rose 40% to $1,808M. The release and the 10-Q both attribute the gain primarily to higher US net price from lower rebates and favourable channel mix. On the call, the CFO described the quarter's gross-to-net picture as broadly unchanged except for Eliquis, where the effect of the January list-price cut began to show in the third quarter.

"So the performance that we are seeing is, for most part, driven by strong market performance and volume rather than dynamics around the gross-to-net." — Cecile Guegan, Chief Financial Officer

The calendar around the product is crowded. The Medicare negotiated price took effect on January 1, 2026. The CFO named Eliquis as an international exclusivity loss at the end of 2026, the 10-Q says a 340B pilot beginning in January 2027 is expected to include it, and the US exclusivity loss follows in 2028.

Assessment: "For most part" is accurate by product count and misleading by dollars. The single largest contributor to the quarter's growth was a gain driven primarily by net price on an asset with three negative pricing or exclusivity events in the next eighteen months. Without Eliquis and COVID, revenue grew 4.4%, which is roughly the core growth rate we underwrote at initiation. That is still good, and the launched portfolio below is the real story, but investors should not capitalise a 40% US Eliquis quarter.

3. Launched and Acquired Products Now Out-Earn the Cliff

The launched and acquired cohort delivered $3.8B and grew 32% operationally, up from $3.2B and 18% in the second quarter. Acquired products grew 37% operationally, and the legacy Seagen US portfolio grew 39%. Padcev ($255M of growth), Nurtec ($135M) and Lorbrena ($114M) led.

"Our launched and acquired product contributed $3.8 billion in revenues. And grew 32% operationally in the quarter, primarily driven by Padcev of $255 million NURTEC $135 million and Lorbrena, $114 million. We continue to invest behind this group of products to mitigate LOE headwinds over the next several years." — Cecile Guegan, Chief Financial Officer

Assessment: This is the most important number in the report for the long-term thesis. At $3.8B a quarter the cohort annualizes near $15.2B, which for the first time exceeds the roughly $14–15B of exclusivity losses management sized after the Vyndamax settlement. Some of the quarter is seasonal, since Prevnar 20 pediatric and Abrysvo sit in the cohort, so we would treat $14–15B as the honest run rate. Even so, the offset engine has caught the cliff in run-rate terms, which is the milestone we have been tracking since initiation.

4. Prevnar: The Explanation Arrives, and It Is Competitive

Prevnar fell 10% operationally to $1,564M, with US revenue down 11%. For the first time in our coverage the release names market share erosion in the adult indication as a cause, alongside lower adult and pediatric vaccination rates in the US and lower pediatric demand in some international markets.

"driven primarily in the U.S. by lower vaccination rates in the adult and pediatric indications, as well as market share erosion for the adult indication; and by lower demand in the pediatric indication in certain international markets." — Pfizer third-quarter 2026 earnings release

Management's answer is the next-generation programme. The 25-valent pediatric candidate posted Phase 2 data in October, and the company now models non-inferiority on the stricter FDA criterion for at least 22 of 25 serotypes in Phase 3.

"Given the Phase 2 results and tighter confidence intervals expected with a much larger sample size in Phase 3, modeling predicts this criterion will be met for at least 22 of 25 serotypes in our pivotal study." — Chris Boshoff, Chief Scientific Officer

Assessment: This closes one of our standing questions, and not favourably. The "order timing" explanation offered at initiation is gone and has been replaced by share loss in adults, which is structural rather than temporary. A $6B-plus franchise losing adult share in the US while the replacement is years from licensure is a slow-moving drag on the Primary Care line that the guidance raise has so far absorbed.

5. COVID: Narrower Recommendations, Same $4B

Comirnaty fell 29% operationally to $808M on a lower favourable US returns adjustment, lower US utilization under narrower vaccine recommendations, and lower international contract deliveries. The FDA approved the 2026–2027 formula in August for adults 65 and older and for people aged 5 to 64 with at least one high-risk condition. Paxlovid fell 63% to $449M, helped by emerging-market purchase timing. Both beat the tracked estimates.

"We are reaffirming our expectation of approximately $4 billion for the COVID products" — Cecile Guegan, Chief Financial Officer

Assessment: Nine-month COVID revenue is $1,957M, so the reaffirmed figure needs about $2.0B in the fourth quarter, down from $2,489M a year ago. With the eligible US population formally narrowed, that is achievable but not conservative, and it is the most likely source of a small fourth-quarter revenue miss. The guidance range is wide enough to absorb it.

6. Cost Programmes Against an Operating Line That Will Not Fall

Management said it remains on track to deliver nearly all of the $7.2B of net savings from its first-phase programmes by the end of 2026, with a further $2.5B from 2027 to 2029. Yet adjusted SI&A plus R&D over nine months rose about 6%, to $17,588M from $16,658M, because R&D grew 14% while SI&A fell 1%.

"We are making meaningful progress with our productivity initiatives and remain on track to deliver nearly all of the anticipated $7.2 billion of net savings by the end of 26 for ongoing cost improvement programs." — Cecile Guegan, Chief Financial Officer

Third-quarter adjusted SI&A rose 2% operationally on a smaller favourable healthcare-reform fee adjustment than last year, which the CFO described as one-time, and she reiterated that full-year SI&A should decline.

Assessment: The savings are real but they are funding the pipeline, not the margin. That is the right allocation, and it is visible in the gross margin and SI&A lines. But the cost programmes should be read as protecting margins through the exclusivity losses rather than expanding them, which is precisely how the CFO framed the next phase in Q&A.

7. A Permanent CFO, the Same Capital Framework, and a Dividend Covered Once

Cecile Guegan was elected Chief Financial Officer effective November 1 after serving as interim CFO from mid-August, which resolves one of our items to watch. Leverage ended the quarter at 2.6x, slightly below the 2.7x target, and business-development capacity is about $6B after the Innovent deal. No shares were repurchased, the $3.3B authorization is untouched, and guidance assumes no buybacks in 2026.

"Our third quarter year to date 2026 operating cash flow was $8.8 billion and leverage ended the quarter at 2.6x slightly below our 2026 target of 2.7x. Given the impact of upcoming LOEs, we expect leverage to remain around current levels, or modestly higher during the LOE transition period." — Cecile Guegan, Chief Financial Officer

The 10-Q fills in the cash picture. Nine-month operating cash flow of $8,825M less $1,542M of capital spending leaves free cash flow of about $7,283M, against $7,347M of dividends paid. A year ago the same arithmetic gave $4,572M against $7,326M.

Assessment: The appointment is the right outcome: an insider with Wyeth, oncology and R&D finance experience who has already delivered two guidance changes. On capital, free cash flow now covers the dividend about once, a marked improvement on last year, with the ViiV sale proceeds sitting in investing cash flow on top. That is adequate for the CEO's August commitment, though not generous, and it explains why buybacks stay deferred until after the exclusivity period.

8. MEVPRO-1 Slips to the First Quarter

The pivotal MEVPRO-1 study of mevrometostat in metastatic prostate cancer, which we flagged as the most consequential near-term catalyst, is event-driven, and events are accruing more slowly than planned. The readout moved from the fourth quarter of 2026 to around February 2027, and MEVPRO-2 to the fourth quarter of 2027.

"These include a readout from MEVPRO-1, which based on the current event rate is now expected in the first quarter of 27." — Chris Boshoff, Chief Scientific Officer

Asked whether the Phase 3 formulation, taken with food to lower peak exposure, could dilute the effect, management said it was confident in the pharmacokinetics.

"So we are very confident in the PK data and the dose that was selected for the phase 3 study." — Chris Boshoff, Chief Scientific Officer

Assessment: Slower event accrual in a progression-free survival study can mean patients are progressing more slowly in both arms, so the delay is not a negative signal in itself. But it moves the catalyst we named as a re-rating trigger out of the period in which our August fair value was supposed to be realized. The stock reached that range anyway, which means the readout is now upside optionality on a fairly valued stock rather than the mechanism for closing a discount.

9. Oncology Pipeline Breadth: Elrexfio, Atirmociclib and the PD-1xVEGF Bispecific

The quarter's pivotal readout was positive. In MagnetisMM-32, Elrexfio monotherapy beat investigator's choice of three standard regimens on progression-free survival in relapsed myeloma after anti-CD38 therapy and lenalidomide. Management said a planned move into earlier lines could expand the eligible population about five-fold, subject to further trials. The CDK4-selective atirmociclib cut the risk of progression or death by 40% in a Phase 2 study of heavily pretreated patients, with fewer dose reductions than approved CDK4/6 inhibitors in cross-trial comparison. The PD-1xVEGF bispecific licensed from 3SBio showed confirmed response rates around 80% in first-line lung cancer with chemotherapy, with two Phase 3 studies running and two more starting this year.

"At the time of the interim analysis, more than 75% of patients receiving Elrexfio had not experienced disease progression or death from any cause, and the estimated 18-month progression free survival rate was approximately 68%." — Chris Boshoff, Chief Scientific Officer

Assessment: After the second-quarter lung-cancer failure, this quarter delivered a positive key pivotal readout, two label expansions and no write-offs, which restores the oncology half of our pipeline pillar. Elrexfio is the asset where the Street is most clearly below management, and the remaining MagnetisMM-5 data due before year-end is the next test of whether the infection-related deaths that clouded that trial are a solved problem.

10. Immunology, Obesity and Vaccines: The Rest of the Late-Stage Slate

The trispecific tilrekimig posted Phase 2 atopic dermatitis data with a placebo-adjusted EASI-75 response of about 50% at the top monthly doses, and Phase 3 is under way, including a head-to-head study against the category leader, with readouts in the respiratory studies expected in 2028 and 2029. In obesity, ten Phase 3 trials of berobenatide are active or planned this year, the amylin combination Phase 2b is fully enrolled with efficacy data in the second half of 2027, and ecnoglutide, which Pfizer sells in China, gained a type 2 diabetes approval in China at the end of October. The Lyme vaccine filing was validated in Europe, with an opinion expected in 2027 and an FDA update promised in the fourth quarter.

"At the top monthly doses, tilrekimig treatment led to placebo adjusted response rate of about 50% for EASI-75, defined as a 75% or greater improvement in the eczema area and severity index." — Chris Boshoff, Chief Scientific Officer

"We are working toward the first in a series of potential approvals for berobenatide in 2028." — Albert Bourla, Chairman & CEO

Assessment: None of this moves 2027 numbers, and our valuation gives it no explicit credit. What it does is answer the question the second quarter raised about whether the pipeline was a single-asset bet. It is not: there are now credible late-stage programmes in four therapeutic areas, and obesity is in an execution phase with no readout risk until 2027.

11. 2027 and Policy After the Midterms

The 2027 guide arrives in mid-December. The CFO listed the headwinds without sizing them: US exclusivity losses for Ibrance and Xtandi, international Eliquis, IRA negotiated prices for two products, a 340B credit-rebate model starting in January, and the effect of the most-favoured-nation agreements. The 10-Q adds that the 340B pilot is subject to litigation and that the company is evaluating its impact.

"The Department of Health and Human Services (HHS) has announced a 340B pilot program, expected to begin in January 2027, that is expected to include Eliquis, Ibrance and Xtandi." — Pfizer third-quarter 2026 Form 10-Q

On policy, the CEO said he expects no change to the pricing agreements and contrasted his current confidence with his alarm a year earlier. The 10-Q confirms the tariff rate on Pfizer products under the Section 232 order is zero until January 20, 2029. The election on the day of the call returned Democratic majorities in both chambers, which leaves a divided government of the kind the CEO described.

"Pursuant to the agreements, the applicable tariff rate under the April 2, 2026 Section 232 Executive Order for Pfizer products will be zero until January 20, 2029." — Pfizer third-quarter 2026 Form 10-Q

Assessment: Policy risk has genuinely receded, and we would downgrade the pricing bear point if the 2027 guide shows the agreements and 340B pilot are manageable. But 2027 stacks two US exclusivity losses, two negotiated prices and a new 340B mechanism onto three of the company's eight largest products. With FY2027 consensus near $2.90 and one tracked FY2028 estimate near $2.48, the market already assumes earnings fall for two more years, and December will test how much of that is already in the price.

Guidance & Outlook

The revenue raise is driven entirely by the non-COVID business, since the COVID assumption is unchanged. On EPS, the narrowed range lifts the floor by $0.15 and the ceiling by $0.05. The guidance also embeds about $1.1B of 2026 revenue lost to generic and biosimilar competition. Against 2025's $62,579M of revenue and $3.22 of adjusted EPS, the midpoints imply revenue up about 0.7% and adjusted EPS down about 6.8%: the trough year is now a shallow one.

Implied Q4 ramp: the range implies fourth-quarter revenue of $15.9B to $17.9B and adjusted EPS of $0.56 to $0.66. At the midpoints, $16.9B and $0.61 compare with $17,557M and $0.66 in the fourth quarter of 2025, with about $2.0B of COVID revenue still to come.

Street at: full-year adjusted EPS consensus moved from about $2.96 before the print to about $3.01, in the upper half of the new range, with revenue near $62.7B. For 2027 the Street sits near $2.90 on revenue of about $59.9B.

Guidance style: Conservative, as it has been all year. An EPS raise smaller than the beat that prompted it, and an implied fourth quarter at or below the prior year, are the signature of a management team setting bars it expects to clear. That conservatism will matter more in December than it does now.

Analyst Q&A Highlights

How much of the quarter was price rather than volume

The first financial question asked directly whether gross-to-net benefits, including any 340B effect, had flattered US sales, and what US net pricing looks like from here. The CFO answered that the quarter was volume-driven apart from Eliquis, and deferred the forward view to the 2027 guide.

Q: "Could you comment on any gross to net benefits to net sales in the third quarter, including from any 340B-related upside. And discuss US net price prospects looking forward in the near term?"
— David Risinger, Leerink Partners

A: "So as it relates to the pricing in Q3, with the exception of, as we were expecting, the impact on Eliquis which started in, Q3, of the January wholesale acquisition cost (WAC) price decrease I would say there is not really any very material change into our gross-to-net Dynamics during the third quarter. So the performance that we are seeing is, for most part, driven by strong market performance and volume rather than dynamics around the gross-to-net."
— Cecile Guegan, Chief Financial Officer

Assessment: The answer is technically consistent with the release but frames the exception as minor when it was the single largest growth driver. Eliquis supplied about half of the non-COVID growth, and the release attributes it primarily to net price. The honest reading is that the portfolio grew on volume and the headline growth rate leaned on Eliquis, where net price was the primary driver.

The shape of 2027 ahead of formal guidance

The closing questions asked for qualitative framing of 2027 and for an explanation of the gap between management's long-term growth aim and Street models. The CFO listed the drivers without numbers and confirmed the guidance date.

Q: "First, just on 2027, appreciate the context provided earlier on price dynamics with respect to IRA and 340B, etcetera. But just any additional high level qualitative framing on other pushes and pulls next year to be aware of ahead of formal guidance?"
— Asad Haider, Goldman Sachs

A: "So we will provide 2027 guidance around middle of December like we did last year. So I will only point out, provide high-level key drivers that we are seeing in 2027. it is 1 obviously the LOE impact not only in The US with Ibrance and Xtandi, some other product, but also in international where we are seeing Eliquis being at the end of 26."
— Cecile Guegan, Chief Financial Officer

Assessment: Nothing new was disclosed, but the list itself is the message: every major 2027 item named is a headwind except the launched portfolio and the cost programme. A management team that has guided conservatively all year is unlikely to change style for the hardest year of the transition, which argues for a December guide below the current Street figure rather than above it.

Why total operating expense has not fallen

A pointed question noted that combined SG&A and R&D is roughly where it was in 2022 despite years of cost programmes, and asked how that squares with protecting the dividend through the exclusivity losses. The CFO explained the reinvestment and conceded the margin direction.

Q: "But then I recall David before he moved on, had mentioned, that majority of the total net cost savings of $7.2 billion will be delivered by the end of 26. So when I look now back at the Pfizer p and l, I am seeing SG&A and R&D was about $24.5 billion back in 2022."
— Umer Raffat, Evercore ISI

A: "Going forward, we have announced our second phase of the program with a $2.5 billion of savings. Both in SG and A and in our cost of manufacturing. Those will translate into savings. So we are expecting to see those translating and mitigating the margin erosion as part of the LOE transition in 2027 to 2029."
— Cecile Guegan, Chief Financial Officer

Assessment: "Mitigating the margin erosion" is the most candid phrase of the call. It confirms that the cost programmes are a defensive tool for 2027 to 2029, not a source of earnings growth, and that the operating-expense base will stay near $24–25B while R&D absorbs the savings. That supports the dividend commitment but caps the earnings leverage the bull case sometimes assumes.

Where the marginal dollar goes under the new CFO

Questioning asked whether the incoming CFO would change the inherited capital framework and where she sees the best return between R&D, bolt-on deals, deleveraging and buybacks. The answer was continuity.

Q: "Cecile, so did you inherit, the capital allocation framework kind of established by your predecessor, how do you think about the marginal dollar that you can kind of invest from here between internal R and D and other bolt on you talked about BD capacity deleveraging, and eventually restarting buybacks."
— Evan Seigerman, BMO Capital Markets

A: "So through the LOE period, our operating cash flow, financial asset and access to capital market will give us the ability to continue to invest and maintain the dividend. As we go post the LOE period, our operating cash flow grows with the levers and we have other option to continue to increase shareholder value. And in that situation, share repurchases become, again, 1 of the levers that we have in order to be able to continue enhance that value for shareholders."
— Cecile Guegan, Chief Financial Officer

Assessment: Buybacks are now explicitly a post-exclusivity-period lever, which on the company's own timeline means after 2028. The answer also uses "maintain the dividend" for the transition years, consistent with the August commitment to hold it and grow it afterwards. Nothing here revives the buyback pillar we marked broken last quarter.

Why not another large acquisition

A historical challenge noted that most of the company's best products came through large deals and asked why a major transaction is not the priority. The answer committed to bolt-ons.

Q: "So given this history, why does not Pfizer make another big deal its primary focus, or would you say that the pipeline is significantly better now than any time in the last 25 years?"
— Steve Scala, TD Cowen

A: "As we look at BD going forward, and considering our capital allocation priorities, our focus is really on more bolt-on acquisitions that are going to complement the large and rich portfolio that we have in the 4 therapeutic areas that we are having."
— Cecile Guegan, Chief Financial Officer

Assessment: With about $6B of capacity and leverage expected to stay near current levels through the transition, bolt-ons are what the balance sheet allows, so the answer is as much constraint as strategy. For shareholders that is mildly positive: it limits the risk of another large impairment cycle and keeps the dividend first in line for cash.

The MEVPRO-1 timeline after the slip

The same exchange asked whether the delay to the first pivotal prostate study had moved the later ones, and management gave dates and then a commercial case for the asset.

Q: "Given the pushout of MEVPRO-1, were there any changes to MEVPRO-2 and -3 timelines?"
— Steve Scala, TD Cowen

A: "Mevrometostat for us is a fully global opportunity. In The US and outside The US. So that is very significant, and exciting. Second, as Chris mentioned, MEVPRO-2 and -3, across MEVPRO-1, -2 and -3, I think we have the potential to position mevrometostat as a multi indication franchise."
— Aamir Malik, Chief U.S. Commercial Officer

Assessment: Management answered the timing question with a commercial pitch, which is understandable but does not change the fact that the readout moved out of 2026. The economic point holds from last quarter: a wholly owned global product is worth more to Pfizer than its US-only half of Xtandi. That makes February the most important single date on the 2027 calendar.

Drug-pricing policy on Election Day

A policy question, asked on the day of the midterm vote, sought management's view of risk to the most-favoured-nation agreements in 2027. The CEO said he expected no change.

Q: "But as you look to 2027, what are your thoughts on the potential risks of changes to MFN or perhaps greater scrutiny on the prior OUS, agreements."
— Geoffrey Meacham, Citi

A: "I do not expect any changes in MFN. I think the agreements are signed and are going until the end. Of the term of this government. And I expect that there will be a renewed interest in the congress to investigate several things. But it is. I do not expect policy changes, frankly."
— Albert Bourla, Chairman & CEO

Assessment: The result supports the CEO's read: a divided government makes legislative change to the pricing framework unlikely, while congressional scrutiny is a reputational rather than a financial risk. The next morning's sector rally suggests the market agreed. The remaining policy risk sits in implementation (340B and negotiated prices) rather than in new law.

The gap between management's growth aim and the Street

The final exchange asked which assumptions the Street gets most wrong relative to the company's aim of high-single-digit growth from 2028. The CEO named specific products.

Q: "But consensus numbers are not really modeling that. There does seem to be a disconnect on both revenue and the earnings lines versus your own expectations."
— Asad Haider, Goldman Sachs

A: "I will also mention another example of Elrexfio. Where for a competing product, the street is forecasting $5 billion, and for us $600 million. We aspire to present the profile that is very similar in efficacy and better in tolerability and in side effects. Now remains to be proven but I do not think the $600 million versus every $5 billion is justifiable."
— Albert Bourla, Chairman & CEO

Assessment: The CEO conceded the profile "remains to be proven", which is the right caveat. The argument is reasonable for Elrexfio after two positive Phase 3s, but a CEO arguing that the Street is too low is a familiar posture, and it does not change the 2027 and 2028 arithmetic. It is a case for upside optionality, which we hold at Hold rather than pay for.

What They're NOT Saying

1. No price and volume split for Eliquis: the release and the 10-Q both call higher US net price the primary driver of 40% US growth but give no breakdown, so investors cannot tell how much of the quarter's single largest gain repeats.
2. No dollar sizing of 2027 pricing headwinds: the 340B pilot covering Eliquis, Ibrance and Xtandi, the negotiated prices for Ibrance and Xtandi, and the most-favoured-nation agreements were all named, and none was sized; the 10-Q says the company is evaluating the 340B impact. December's guide will have to carry the full weight of that disclosure.
3. No walk-through of the fourth-quarter phasing: the call did not explain why the raised range implies fourth-quarter adjusted EPS at or below last year's $0.66, beyond noting that most Comirnaty revenue lands in the fourth quarter.
4. No share figure for the Prevnar adult loss: the release names adult market share erosion as a cause for the first time but gives neither the share lost nor the trajectory.
5. No 2027 exclusivity-loss dollar figure: the 2026 guide carries about $1.1B of lost revenue to generics and biosimilars, but the 2027 figure, with Ibrance, Xtandi and international Eliquis all exposed, waits for December.
6. No date for buybacks: repurchases are now a "post the LOE period" lever, and leverage is expected to stay at or modestly above current levels through the transition.
7. No event count for MEVPRO-1: the slip was attributed to the event rate without saying how many of the required events have accrued.

Market Reaction

• Pre-print setup: PFE closed at $30.67 on November 2, 2026, at the top of its 52-week closing range of $23.67 to $30.67. The stock was up 23.2% year to date against 10.2% for the S&P 500, up 10.3% over the trailing 30 days and up 24.4% over the trailing 12 months. Since our August note it had risen 20.7% from $25.41 while the S&P 500 fell 2.5%.
• Reaction session (November 3): the stock opened unchanged at $30.68 and reached $31.05 in the first five minutes, close to the session high of $31.06, then faded steadily through the 10:00 AM call and the afternoon to close at $30.00, down 2.2% or $0.67 and near the $29.89 low. Volume of 53.1M was 1.8x the 30-day average.
• Peers and index: the S&P 500 rose 0.4%, but large-cap pharma fell on Election Day: Merck fell 2.5%, Bristol-Myers 2.1%, Johnson & Johnson 1.6%, AstraZeneca 1.5% and AbbVie 1.0%, with the health care sector ETF down 0.3%.
• Next-day session (November 4): PFE rose 2.6% to $30.79 on 48.3M shares as the group rallied after the vote: Bristol-Myers rose 4.0%, Merck 3.9%, Johnson & Johnson 3.8%, the sector ETF 3.1% and the S&P 500 1.6%. Across the two sessions PFE gained 0.4%, against 2.7% for the sector ETF and 2.0% for the index.

Already in the price. A beat-and-raise met with a fade from the opening high is the classic signature of a stock that ran into the print. PFE entered the quarter at a 52-week high after a 21% run that outpaced both the index and its sector, and the first five minutes were the best of the day. The selling continued through the call rather than reversing after it, which tells us the market was not reacting to any single disclosure but taking profit on a thesis it had already paid for.

The election muddies the first day, not the second. The 2.2% decline on November 3 matched what Merck and Bristol-Myers did without an earnings report, so the reaction-day move is mostly sector positioning ahead of the vote. The cleaner read is the next session. When the group rallied 3% to 5% on a result that leaves the pricing agreements intact, PFE lagged most of its large-cap peers. Over two days it underperformed its sector by more than two points despite a beat-and-raise.

What would move it from here. The tape says incremental good news on the current year no longer moves the stock. The next two catalysts are dated and binary in character: the 2027 guide in mid-December, and MEVPRO-1 around February. Neither is likely to be fully priced ahead of time, and both can move a stock at fair value in either direction.

Street Perspective

Debate: Is the growth repeatable into 2027?

Bull view: The bull case points to a 32% operational gain in launched and acquired products and a cohort now annualizing above the size of the exclusivity losses, and argues that this engine, not Eliquis, will set the trajectory from here. Two consecutive raises are evidence that guidance is conservative.

Bear view: The bear camp notes that Eliquis, primarily on net price, produced about half of the non-COVID growth, that the same product faces international generics, a 340B pilot and US exclusivity loss within eighteen months, and that 2027 adds two more US exclusivity losses and two negotiated prices.

Our take: Both are right about different time frames. The launched portfolio is genuinely strong, and it is the reason we expect 2027 to be a shallow decline rather than a cliff. But the headline 7% will not repeat in 2027; the 4.4% ex-Eliquis rate is the better guide to the core, and it is fully in today's consensus.

Debate: Has the re-rating run its course?

Bull view: The optimistic view holds that roughly 10x earnings and a mid-5% yield remain a steep discount to large-cap pharma peers, and that a stock with improving revisions, a secure dividend and a deep pipeline deserves to close more of that gap.

Bear view: The skeptics argue that the discount reflects a real earnings decline through 2028, that the stock trades above the average sell-side target, and that a 21% run against a falling index leaves little room for disappointment in December.

Our take: We side with the skeptics on timing, not on the business. The peer discount is structural while earnings fall, and it will narrow when the trough visibly ends rather than before. At 10.3x 2026 and about 12x a tracked 2028 estimate, the stock already prices a successful transition.

Debate: Does the Street under-model the post-2028 portfolio?

Bull view: The constructive camp takes management's side: thin pipeline coverage, low Street forecasts for products such as Elrexfio and Nurtec, and a slate of late-stage programmes in four therapeutic areas point to a growth rate after 2028 well above what models assume.

Bear view: The counter is that management has made long-range promises before, that the second-quarter sigvotatug vedotin lung-cancer readout failed, and that the high-single-digit aim is risk-adjusted by the company itself with no external check.

Our take: We think the Street is probably too low on the launched portfolio and about right on the pipeline. The difference will show up one readout at a time, starting with MEVPRO-1 and the second Elrexfio dataset. That is a reason to keep the stock on the upgrade list, not a reason to pay for 2030 in 2026.

Model Update Needed

Valuation impact: At $30.79 the stock trades at 10.3x the new 2026 adjusted EPS midpoint of $3.00. On the same 2026 basis, our August note reiterated Outperform at 8.8x ($25.41 on a $2.90 midpoint). On 2027 consensus of about $2.90 the stock is at 10.6x, and on one tracked 2028 estimate of about $2.48, the year US Eliquis exclusivity ends, about 12.4x. Re-deriving fair value with the same 10x to 10.7x band we applied in August, now on the raised $3.00 midpoint, gives $30.00 to $32.10, which we round to $30–32 (10.3x to 11.0x 2027 consensus). That new range sits at the level our August note called fair value, and the stock is already inside it. From $30.79, the bottom of the range implies about 3% price downside, the midpoint about 1% upside and the top about 4%; adding the 5.6% dividend yield, the expected 12-month total return is roughly 3% to 10%, or about 6% at the midpoint. That is a market-like return, and it is the reason for the downgrade.

Thesis Scorecard Post-Earnings

The scorecard grades the same ten pillars carried in our standing thesis since the second quarter, then the commitments and rating triggers we published in August.

Grading last quarter's commitments

Grading the rating triggers we published in August

Overall: The fundamental thesis is stronger than at any point in our coverage. Five of the eight commitments graded either delivered or remain on schedule, the offset engine has caught the exclusivity cliff in run-rate terms, the pipeline pillar recovers, and free cash flow covers the dividend about once (0.99x). The pillar that weakened is valuation, and it weakened for the best possible reason: the market moved toward our view. The downgrade is not one of the triggers we published in August firing. It follows from the price reaching the fair value range that note set, and we say so plainly rather than move the target to keep the rating.

Action: Downgrade to Hold from Outperform, with a fair value of $30–32 and a constructive tilt. Our 2027 adjusted EPS estimate is $2.80–3.00. New triggers, all outside that range: we would return to Outperform if the stock falls below $27 with the fundamentals intact, or if MEVPRO-1 succeeds at or above its disclosed bar and the 2027 guide midpoint comes in above $3.00. We would move to Underperform if the dividend commitment were walked back (unchanged from August), or if the 2027 guide midpoint falls below $2.70 and MEVPRO-1 fails. If MEVPRO-1 succeeds but the 2027 guide lands below $2.70, the two offset and we stay at Hold.